US 11,692,012 B2
Human cytomegalovirus comprising exogenous antigens
Klaus Frueh, Portland, OR (US); Scott G. Hansen, Portland, OR (US); Jay Nelson, Lake Oswego, OR (US); Louis Picker, Portland, OR (US); and Patrizia Caposio, Beaverton, OR (US)
Assigned to Oregon Health & Science University, Portland, OR (US)
Filed by Oregon Health & Science University, Portland, OR (US)
Filed on Mar. 26, 2021, as Appl. No. 17/214,598.
Application 17/214,598 is a continuation of application No. 16/545,561, filed on Aug. 20, 2019, granted, now 10,995,121.
Application 16/545,561 is a continuation of application No. 15/326,444, granted, now 10,428,118, issued on Oct. 1, 2019, previously published as PCT/US2015/040807, filed on Jul. 16, 2015.
Claims priority of provisional application 62/025,348, filed on Jul. 16, 2014.
Prior Publication US 2022/0064225 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/045 (2006.01); A61K 39/12 (2006.01); C12N 15/86 (2006.01); A61K 35/33 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C12N 15/85 (2006.01); A61K 39/21 (2006.01); C07K 14/16 (2006.01); A61P 35/00 (2006.01)
CPC C07K 14/045 (2013.01) [A61K 35/33 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 39/21 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/572 (2013.01); A61P 35/00 (2018.01); C07K 14/161 (2013.01); C12N 2710/16143 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/16234 (2013.01)] 30 Claims
 
1. A recombinant human cytomegalovirus (HCMV) comprising:
(1) a first nucleic acid encoding at least one heterologous antigen;
(2) an inactivating mutation in the UL45 gene; and
(3) active US2, US3, US6, US7, UL97, and UL131A genes;
wherein the recombinant HCMV is a genetically modified TR strain of HCMV; and the recombinant HCMV is ganciclovir-sensitive.